Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 12/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR1E | P28566 | 1/20 | 0.43 |
| ▸ | HTR1F | P30939 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708227 | 0.93 | KEAP1 (0.55) | KEAP1NFE2L2PGRHTR6HTR1A | |
| SCHEMBL21708287 | 0.88 | KEAP1 (0.55) | KEAP1NFE2L2PGRHTR6MAPT | |
| SCHEMBL21734439 | 0.88 | KEAP1 (0.53) | KEAP1NFE2L2PGRL3MBTL1MAPT | |
| SCHEMBL21734725 | 0.86 | KEAP1 (0.60) | KEAP1NFE2L2PGRMAPT | |
| SCHEMBL21708233 | 0.86 | KEAP1 (0.55) | KEAP1NFE2L2PGRMAPT | |
| SCHEMBL21708313 | 0.86 | KEAP1 (0.48) | KEAP1NFE2L2 | |
| SCHEMBL21734454 | 0.84 | KEAP1 (0.49) | KEAP1NFE2L2PGRHTR6HTR1A | |
| SCHEMBL21708282 | 0.84 | KEAP1 (0.56) | KEAP1NFE2L2L3MBTL1MAPT | |
| SCHEMBL21708276 | 0.84 | KEAP1 (0.53) | KEAP1NFE2L2HTR6L3MBTL1 | |
| SCHEMBL21734440 | 0.82 | KEAP1 (0.59) | KEAP1NFE2L2PGRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | claimed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | claimed |
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | disclosed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | FLNA, FLNB, BRI3BP | KEAP1 3844/4885NFE2L2 3888/4885PGR 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.